文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

SGLT2抑制剂与GLP-1受体激动剂对2型糖尿病患者肾脏结局的比较

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论目标试验模拟显示,2型糖尿病患者起始SGLT2i较GLP-1RA的5年CKD风险更低(6.7% vs 8.2%)、5年AKI人均事件数更少(每100人25.2 vs 28.7)。

该研究采用目标试验模拟设计,基于丹麦全国人群数据,纳入2014年1月至2020年11月起始SGLT2i或GLP-1RA治疗、接受二甲双胍治疗的2型糖尿病患者,随访至2024年10月。共36 279人起始SGLT2i、18 782人起始GLP-1RA。加权5年CKD风险SGLT2i组6.7%、GLP-1RA组8.2%(风险比0.81,95%CI 0.76-0.87);5年每100人AKI平均累积事件数分别为25.2与28.7(MCC比0.88,95%CI 0.83-0.93)。次要结局白蛋白尿和死亡在GLP-1RA起始者中略低。作者认为SGLT2i对2型糖尿病肾脏病一级预防具有潜在价值。

要点

  • 2型糖尿病患者起始SGLT2i vs GLP-1RA:加权5年CKD风险6.7% vs 8.2%(风险比0.81,95%CI 0.76-0.87;风险差-1.5%,95%CI -2.0%至-1.0%)。
  • 5年每100人AKI平均累积事件数SGLT2i组25.2 vs GLP-1RA组28.7(MCC比0.88,95%CI 0.83-0.93;MCC差-3.5,95%CI -5.0至-2.0)。
  • 次要结局白蛋白尿和死亡在GLP-1RA起始者中略低。
  • 亚组结果一致,无既存肾脏病者中SGLT2i的CKD和AKI降低最明显。
  • 作者认为SGLT2i治疗对2型糖尿病个体肾脏病一级预防具有潜在价值。

适用人群与场景

  • 丹麦全国人群数据中接受二甲双胍治疗的2型糖尿病成人,2014年1月至2020年11月起始SGLT2i或GLP-1RA治疗,随访至2024年10月。
  • SGLT2i起始者36 279人,中位年龄63岁(IQR 55-71);GLP-1RA起始者18 782人,中位年龄61岁(IQR 52-70);两组糖尿病病程、eGFR和尿白蛋白-肌酐比可比。

研究设计与关键结果

  • 设计:目标试验模拟的比较效果研究,使用丹麦全国人群数据;意向性治疗效应采用逆概率治疗加权估计,CKD风险用Aalen-Johansen估计量,AKI负担用平均累积计数(MCC,人均事件数,因AKI可多次发生)。
  • 主要终点之一CKD(eGFR下降40%、严重白蛋白尿或肾衰竭):加权5年风险SGLT2i组6.7%(95%CI 6.4%-7.0%)vs GLP-1RA组8.2%(95%CI 7.8%-8.6%),风险比0.81(95%CI 0.76-0.87),风险差-1.5%(95%CI -2.0%至-1.0%)。
  • 共同主要终点AKI:5年每100人MCC SGLT2i组25.2(95%CI 24.4-26.1)vs GLP-1RA组28.7(95%CI 27.4-30.0),MCC比0.88(95%CI 0.83-0.93),MCC差-3.5(95%CI -5.0至-2.0)。
  • 次要结局:白蛋白尿和死亡在GLP-1RA起始者中略低。
  • 亚组分析(按既存心血管或肾脏病分层)结果一致,无既存肾脏病者中SGLT2i的CKD和AKI降低最明显。

证据类型、等级与局限

  • 证据类型:基于丹麦全国人群数据的目标试验模拟比较效果研究。

对床旁实践的改变

  • 作者认为,SGLT2i治疗对2型糖尿病个体肾脏病一级预防具有潜在价值。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: No randomized clinical trial has directly compared the effectiveness of sodium-glucose cotransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in reducing acute and chronic kidney outcomes.

OBJECTIVE: To examine the comparative effectiveness of SGLT2i and GLP-1RA treatment for acute and chronic kidney outcomes in individuals with type 2 diabetes.

DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study with a target trial emulation design used nationwide, population-based data from Denmark. Participants were individuals with metformin-treated type 2 diabetes who initiated SGLT2i or GLP-1RA treatment from January 2014 to November 2020, with follow-up through October 2024.

EXPOSURE: Initiation of an SGLT2i or a GLP-1RA.

MAIN OUTCOMES AND MEASURES: The 2 coprimary outcomes were chronic kidney disease (CKD; 40% reduction in estimated glomerular filtration rate [eGFR], severe albuminuria, or kidney failure) and acute kidney injury (AKI). Secondary outcomes included the individual components of CKD, albuminuria, and death. Intention-to-treat effects were estimated using inverse probability of treatment weights, comparing risks for CKD assessed by the Aalen-Johansen estimator, and AKI burden by mean cumulative counts (MCCs; mean number of events per individual as multiple AKI events were possible). Subgroup analyses included stratification by preexisting cardiovascular or kidney disease.

RESULTS: The study included 36 279 individuals who initiated an SGLT2i and 18 782 who initiated a GLP-1RA (median [IQR] age, 63 [55-71] years vs 61 [52-70] years), with comparable diabetes duration, eGFR, and urine albumin-creatinine ratios. The weighted 5-year risk of CKD was 6.7% (95% CI, 6.4%-7.0%) for SGLT2i initiators and 8.2% (95% CI, 7.8%-8.6%) for GLP-1RA initiators (risk ratio: 0.81 [95% CI, 0.76-0.87]; risk difference: -1.5% [95% CI, -2.0% to -1.0%]). The 5-year MCC of AKI per 100 individuals was 25.2 (95% CI, 24.4-26.1) for SGLT2i initiators and 28.7 (95% CI, 27.4-30.0) for GLP-1RA initiators (MCC ratio: 0.88 [95% CI, 0.83-0.93]; MCC difference: -3.5 [95% CI, -5.0 to -2.0]). In contrast, the secondary outcomes of albuminuria and mortality were slightly reduced in GLP-1RA initiators. Results were consistent across subgroups, with the most pronounced CKD and AKI reductions with SGLT2i observed among individuals without preexisting kidney disease.

CONCLUSIONS AND RELEVANCE: This comparative effectiveness study found that initiation of SGLT2i vs GLP-1RA treatment in individuals with type 2 diabetes was associated with a lower 5-year risk of CKD and a lower 5-year count of AKI. These findings underscore the potential of SGLT2i treatment for primary prevention of kidney disease in individuals with type 2 diabetes.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Jensen SK, Heide-Jørgensen U, Andersen IT, et al. SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes. JAMA Intern Med. 2026. PMID: 41557360. doi:10.1001/jamainternmed.2025.7409

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。